Cytomegalovirus vaccine development

Current Topics in Microbiology and Immunology

Volumn 325, Issue , 2008, Pages 361-382

  Schleiss, M R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD 169; AD 169 VACCINE; BACTERIAL ARTIFICIAL CHROMOSOME VACCINE; BENZALKONIUM CHLORIDE; CANARYPOX VECTOR; CHOLERA TOXIN; CRL 1005; CYTOMEGALOVIRUS VACCINE; DENSE BODY VACCINE; DNA POLYMERASE; DNA VACCINE; GENE PRODUCT; GLYCOPROTEIN B VACCINE; GLYCOPROTEIN H VACCINE; GLYCOPROTEIN L VACCINE; GLYCOPROTEIN M VACCINE; GLYCOPROTEIN N VACCINE; GLYCOPROTEIN O VACCINE; HELICASE; IMMEDIATE EARLY 1 VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEPTIDE VACCINE; PHOSPHOPROTEIN 65 VACCINE; POLOXAMER; RECOMBINANT VACCINE; SUBUNIT VACCINE; TOWNE VACCINE; UL 105; UL 54; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE TRANSFER; BACTERIAL ARTIFICIAL CHROMOSOME; CLINICAL TRIAL; CONGENITAL INFECTION; CRL 1005; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FETUS; HEALTH CARE COST; HEALTH EDUCATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNITY; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; MATERNAL CARE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SURGICAL PATIENT; TRANSGENIC PLANT; VACCINATION; VIRUS TRANSMISSION; IMMUNE DEFICIENCY; IMMUNOLOGY; MEDICAL RESEARCH;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

BIOMEDICAL RESEARCH; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 48849085876     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-77349-8_20     Document Type: Review

References (70)

1. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26-32
2. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180:843-846
3. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U (2006) Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87:2451-2460
4. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39:233-239
5. BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ (2000) Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 61:764-779
6. Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S, Plotkin S (2001) A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183:1171-1179
7. Bernstein DI, Schleiss MR, Berencsi K, Gonczol E, Dickey M, Khoury P, Cadoz M, Meric C, Zahradnik J, Duliege AM, Plotkin S (2002) Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185:686-690
8. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9:543-558
9. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366-1371
10. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079-1085
11. Cannon MJ, Davis KF (2005) Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 5:70
12. Cicin-Sain L, Brune W, Bubic I, Jonjic S, Koszinowski UH (2003) Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol 77:8249-8255
13. Colugnati FA, Staras SA, Dollard SC, Cannon MJ (2007) Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 7:71
14. Demmler GJ (1996) Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis 11:135-162
15. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R (2003) Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77:5226-5240
16. Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin SA, Gonczol E (1999) Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17:50-58
17. th ICAAC; G-543
18. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667
19. Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289:1008-1011
20. Fowler KB, Stagno S, Pass RF (2004) Interval between births and risk of congenital cytomegalovirus infection. Clin Infect Dis 38:1035-1037
21. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, Duliege AM (1999) Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 180:1700-1703
22. Gopal IN, Quinn A, Henry SC, Hamilton JD, Staats HF, Frothingham R (2005) Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. Microbiol Immunol 49:113-119
23. Griffiths PD, McLean A, Emery VC (2001) Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19:1356-1362
24. Hardy CM (2007) Current status of virally vectored immunocontraception for biological control of mice. Soc Reprod Fertil Suppl 63:495-506
25. Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, Prichard M, Wang Z, Yan Q, Sharp MA, Klein N, Arvin AM, Kemble G (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350-1360
26. Ishibashi K, Tokumoto T, Tanabe K, Shirakawa H, Hashimoto K, Kushida N, Yanagida T, Inoue N, Yamaguchi O, Toma H, Suzutani T (2007) Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 45:60-67
27. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP (2006a) Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35:332-337
28. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP (2006b) Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 24:5311-5319
29. Khanna R, Diamond DJ (2006) Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33
30. Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 143:16-25
31. Maschmann J, Hamprecht K, Dietz K, Jahn G, Speer CP (2001) Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis 33:1998-2003
32. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103-110
33. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP (2002) Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21:133-138
34. Morello CS, Ye M, Spector DH (2002) Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication. J Virol 76:4822-4835
35. Morello CS, Ye M, Hung S, Kelley LA, Spector DH (2005) Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J Virol 79:159-175
36. Morello CS, Kelley LA, Munks MW, Hill AB, Spector DH (2007) DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol 81:7766-7775
37. Murph JR, Baron JC, Brown CK, Ebelhack CL, Bale JF Jr (1991) The occupational risk of cytomegalovirus infection among day-care providers. JAMA 265:603-608
38. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362
39. Pass RF (1996) Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis 5:240-244
40. Pass RF, Hutto C, Lyon MD, Cloud G (1990) Increased rate of cytomegalovirus infection among day care center workers. Pediatr Infect Dis J 9:465-467
41. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180:970-975
42. Pepperl S, Munster J, Mach M, Harris JR, Plachter B (2000) Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 74:6132-6146
43. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA Jr, Shope TC, Spector SA, Dankner WM (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:1176-1178
44. Rapp M, Messerle M, Lucin P, Koszinowski UH (1993) In vivo protection studies with mCMV glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA (eds) Multidisciplinary approach to understanding cytomegalovirus disease. Elsevier, Amsterdam, pp 327-332
45. Reap EA, Dryga SA, Morris J, Rivers B, Norberg PK, Olmsted RA, Chulay JD (2007) Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 14:748-755
46. Revello MG, Gerna G (2002) Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15:680-715
47. Schleiss MR, Heineman TC (2005) Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381-406
48. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI (2004) Protection against congenital cytomegalovirus (CMV) infection and disease in guinea pigs conferred by a purified recombinant glycoprotein B (gB) vaccine. J Infect Dis 189:1374-1381
49. Schleiss MR, Stroup G, Pogorzelski K, McGregor A (2006) Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine 24:6175-6186
50. Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF (2007) Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195:789-798
51. Shanley JD, Wu CA (2003) Mucosal immunization with a replication- deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine 21:2632-2642
52. Shanley JD, Wu CA (2005) Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine 23:996-1003
53. Shen S, Wang S, Britt WJ, Lu S (2007) DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 25:3319-3327
54. Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80:4591-4600
55. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF (2007) CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 5:17
56. Soderberg-Naucler C (2006) Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 259:219-246
57. Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23 [Suppl 3]:90-96
58. Stratton KR, Durch JS, Lawrence RS (1999) Vaccines for the 21st century: a tool for decisionmaking, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC
59. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673-685
60. Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR (1999) Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 17:3020-3029
61. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG 2nd, Rodland K, Wiley S, Britt W, Shenk T, Smith RD, Nelson JA (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960-10966
62. Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow DC (2005) I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 16:1143-1150
63. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044
64. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153-18158
65. Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, Diamond DJ (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78:3965-3976
66. Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ (2006) Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35:324-331
67. Whitley RJ (2004) Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 549:155-160
68. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579
69. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702-707
70. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF (2006) Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 35:338-342